利用XBB谱系疫苗推广前的康复者血清估计针对新兴SARS-CoV-2变异株的中和抗体应答
研究利用78份血清样本(XBB.1.5感染前后及XBB谱系疫苗接种前后)检测针对SARS-CoV-2 Victoria和Omicron亚变异株的活病毒微量中和抗体。XBB.1.5感染后BA.2.86中和抗体滴度较感染前升高4倍(几何均值51 vs 210,p ≤ 0.0001);XBB谱系疫苗接种后BA.2.86中和抗体滴度也出现类似升高(几何均值144 vs 600,倍数变化=4.17,p ≤ 0.0001)。结论认为XBB.1.5感染可作为预测XBB谱系疫苗接种后中和应答的合适替代。
要点
- XBB.1.5感染后BA.2.86中和抗体滴度较感染前升高4倍(几何均值51 vs 210,p ≤ 0.0001)。
- XBB谱系疫苗接种后BA.2.86中和抗体滴度较接种前升高(几何均值144 vs 600,倍数变化=4.17,p ≤ 0.0001)。
- XBB.1.5感染是预测XBB谱系疫苗接种后中和应答的合适替代。
核心结论
- XBB.1.5感染是预测XBB谱系疫苗接种后中和应答的合适替代,研究结果可能支持未来疫苗开发和接种策略。
研究设计与样本
- 共检测78份血清样本(XBB.1.5感染前后及XBB谱系疫苗接种前后),采用活病毒微量中和试验检测针对SARS-CoV-2 Victoria和Omicron亚变异株的中和抗体,比较感染/接种前后中和抗体滴度的几何均值(GM)。
主要发现
- XBB.1.5感染后,针对BA.2.86的中和抗体滴度较感染前升高4倍(几何均值51 vs 210,p ≤ 0.0001)。
- XBB谱系疫苗接种后,BA.2.86中和抗体滴度出现类似升高(几何均值144 vs 600,倍数变化=4.17,p ≤ 0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SARS-CoV-2 immune escape variants can alter existing vaccine effectiveness. In September 2023, we aimed to predict the neutralising response against BA.2.86 offered by XBB-lineage vaccines before vaccine roll-out utilising XBB.1.5 convalescent sera. We then assessed the response to XBB-lineage boosters from different individuals in the same cohort. METHODS: A total of 78 sera samples (pre/post-XBB.1.5 infection and pre/post-XBB-lineage vaccination) were tested for live microneutralisation against SARS-CoV-2 Victoria and Omicron subvariants. Geometric means (GM) of neutralising antibody titres (nAbT) pre- and post-infection/vaccination were compared. RESULTS: After XBB.1.5 infection, a 4-fold increase in neutralising antibody titres against BA.2.86 was observed compared to pre-infection titres (GM 51 vs 210, p ≤ 0.0001). A similar increase in BA.2.86 nAbT was seen post-XBB-lineage vaccination (GM 144 vs 600, fold change = 4.17, p ≤ 0.0001). CONCLUSION: XBB.1.5 infection was a suitable proxy to predict the neutralisation response following XBB-lineage vaccination. Our findings may support future vaccine development and vaccination strategies.
引用
- Atti A, England A, Sung J, et al. Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines. Vaccine. 2025. PMID: 39983539. doi:10.1016/j.vaccine.2025.126898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。